Omnicell (NASDAQ:OMCL) Updates FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 1.650-1.850 for the period, compared to the consensus EPS estimate of 1.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Omnicell Stock Up 2.6 %

Shares of Omnicell stock opened at $35.35 on Friday. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of 130.93, a PEG ratio of 7.53 and a beta of 0.85. The firm’s 50-day moving average is $39.16 and its two-hundred day moving average is $42.64.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, research analysts expect that Omnicell will post 1.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

OMCL has been the subject of a number of analyst reports. Benchmark reissued a “buy” rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. Bank of America dropped their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a report on Monday. Wells Fargo & Company decreased their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. cut their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Omnicell currently has an average rating of “Hold” and a consensus target price of $51.00.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.